{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:47:39Z","timestamp":1772106459683,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T00:00:00Z","timestamp":1280793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10549-010-1084-8","type":"journal-article","created":{"date-parts":[[2010,8,2]],"date-time":"2010-08-02T09:34:12Z","timestamp":1280741652000},"page":"785-793","source":"Crossref","is-referenced-by-count":12,"title":["Quality of life in women with metastatic breast cancer during 9\u00a0months after randomization in the TEX trial (epirubicin and paclitaxel w\/o capecitabine)"],"prefix":"10.1007","volume":"123","author":[{"given":"Helene","family":"Svensson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakaria","family":"Einbeigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hatschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"1084_CR1","volume-title":"Collecting quality of life data in EORTC clinical trials-what happens in practice? Guidelines for assessing quality of life in EORTC clinical trials (internal report)","author":"T Young","year":"1999","unstructured":"Young T, De Haes J, Curran D (1999) Collecting quality of life data in EORTC clinical trials-what happens in practice? Guidelines for assessing quality of life in EORTC clinical trials (internal report). Brussels, EORTC"},{"issue":"3","key":"1084_CR2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/(SICI)1099-1611(199905\/06)8:3<260::AID-PON383>3.0.CO;2-Z","volume":"8","author":"J Haes De","year":"1999","unstructured":"De Haes J, Curran D, Young T et al (1999) Quality of life evaluation in oncological clinical trials\u2014the EORTC model The EORTC quality of life study group. Psychooncology 8(3):260\u2013263","journal-title":"Psychooncology"},{"issue":"13","key":"1084_CR3","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/JCO.2004.02.037","volume":"22","author":"A Bottomely","year":"2004","unstructured":"Bottomely A, Biganzoli L, Cufer T et al (2004) Randomized controlled trial investigated short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosfamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study. J Clin Oncol 22(13):2576\u20132586","journal-title":"J Clin Oncol"},{"issue":"7","key":"1084_CR4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","volume":"40","author":"F Efficace","year":"2004","unstructured":"Efficace F, Biganzoli L, Piccart M et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021\u20131030","journal-title":"Eur J Cancer"},{"issue":"2","key":"1084_CR5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-007-9651-3","volume":"109","author":"PA Cassier","year":"2008","unstructured":"Cassier PA, Chabaud S, Trillet-Lenoir V et al (2008) A phase III trial of doxorubicin and dosetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: result of the Erasme 3 study. Breast Cancer Res Treat 109(2):343\u2013350","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1084_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"1084_CR7","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MAD Sprangers","year":"1996","unstructured":"Sprangers MAD, Groenvold M, Arraras JI et al (1996) The EORTC breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756\u20132768","journal-title":"J Clin Oncol"},{"key":"1084_CR8","volume-title":"On behalf of the EORTC quality of life group EORTC QLQ-C30 scoring manual, 3rd edn","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K et al (2001) On behalf of the EORTC quality of life group EORTC QLQ-C30 scoring manual, 3rd edn. EORTC, Brussels"},{"issue":"4","key":"1084_CR9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/028418600750013384","volume":"39","author":"H Michelsson","year":"2000","unstructured":"Michelsson H, Bolund C, Nilssson B, Brandberg Y (2000) Health-related quality of life measured by the EORTC QLQ-C30. Reference values from a large sample of the swedish population. Acta Oncologica 39(4):477\u2013484","journal-title":"Acta Oncologica"},{"issue":"1","key":"1084_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"issue":"12","key":"1084_CR11","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0959-8049(00)00134-9","volume":"36","author":"JA Kramer","year":"2000","unstructured":"Kramer JA, Curran D, Piccart M et al (2000) Randomized trial of paclitaxel versus doxorubicin as first line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36(12):1488\u20131497","journal-title":"Eur J Cancer"},{"issue":"4","key":"1084_CR12","first-page":"769","volume":"16","author":"A Riccardi","year":"2000","unstructured":"Riccardi A, Tinelli C, Brugnatelli S et al (2000) Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective randomizes multicentric study on antitumor effect and quality of life in advanced breast cancer. Int J Oncol 16(4):769\u2013776","journal-title":"Int J Oncol"},{"issue":"11","key":"1084_CR13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0959-8049(00)00126-X","volume":"36","author":"L Hakamies-Blomqvist","year":"2000","unstructured":"Hakamies-Blomqvist L, Luoma M, Sj\u00f6str\u00f6m J et al (2000) Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. Eur J Cancer 36(11):1411\u20131417","journal-title":"Eur J Cancer"},{"issue":"6","key":"1084_CR14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","volume":"19","author":"J Jassem","year":"2001","unstructured":"Jassem J, Pienkowski T, Pluzanska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19(6):1707\u20131715","journal-title":"J Clin Oncol"},{"issue":"28","key":"1084_CR15","first-page":"17081","volume":"23","author":"M Botenbal","year":"2005","unstructured":"Botenbal M, Creemers GJ, Braun HJ et al (2005) Phase II to III study comparing doxorubicin and dosetaxel with fluorouracil, doxorubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer: results of Dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol 23(28):17081\u201317088","journal-title":"J Clin Oncol"},{"issue":"8","key":"1084_CR16","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"S Chan","year":"1999","unstructured":"Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17(8):2341\u20132354","journal-title":"J Clin Oncol"},{"issue":"12","key":"1084_CR17","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1200\/JCO.2000.18.12.2385","volume":"18","author":"B Norris","year":"2000","unstructured":"Norris B, Pritchard KI, James K et al (2000) Phase III comparative study of Vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic\/recurrent breast cancer: National cancer institute of Canada clinical trials group study MA8. J Clin Oncol 18(12):2385\u20132394","journal-title":"J Clin Oncol"},{"issue":"19","key":"1084_CR18","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2003.07.020","volume":"21","author":"Y Brandberg","year":"2003","unstructured":"Brandberg Y, Michelson H, Nilsson B et al (2003) Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, carboplatin or tailored therapy with fluorouracil, epirubicin, cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 21(19):3659\u20133664","journal-title":"J Clin Oncol"},{"issue":"7","key":"1084_CR19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00520-004-0708-0","volume":"13","author":"SM Bang","year":"2005","unstructured":"Bang SM, Park SH, Kang HG et al (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13(7):515\u2013521","journal-title":"Support Care Cancer"},{"issue":"2","key":"1084_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.hoc.2007.03.001","volume":"21","author":"EL Mayer","year":"2007","unstructured":"Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North am 21(2):257\u2013272","journal-title":"Hematol Oncol Clin North am"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1084-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1084-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:32:36Z","timestamp":1559219556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1084-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1084-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,3]]}}}